# Denovo Biopharma

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/denovo-biopharma

- Industry: Biotechnology
- Headquarters: Hangzhou, China
- Website: www.denovobiopharma.com
- Total disclosed funding: $172M
- Latest round: Series D (Dec 8, 2020)
- Investors on record: 17

## About

Established in 2012 and based in Beijing, Denovo Biopharma is a biotechnology company that uses the technology to develop drugs. The company is headquartered in Hangzhou, with a clinical operations center in Beijing and a subsidiary in the United States. Dr. Wen Luo, the company's Chairman and Managing Director, has over 20 years of experience in the biopharmaceutical industry, having worked at Ligand. In May 2024, it raised a strategic funding for approximately USD 12 million.

The company’s main business is the development of antitumor drugs. The company’s self-developed pipeline such as DB102 for glioma, DB106 for acute myeloid leukemia, DB109 for Alzheimer's disease, and DB103 for schizophrenia.

The company generates revenues by providing antitumor and drugs for the treatment of the central nervous system.

The company will use the strategic funding to develop DB107, a gene therapy for brain tumors, which includes a clinical Phase 1/2 trial for glioblastoma (GBM).

## Funding rounds

- Series D, Dec 8, 2020, $46M — China International Capital Corporation, TTGG Ventures, CR Capital, Yingke Private Equity, Sangel Capital, ZCC Asset Management, HosenCare Brothers, Heda Venture, Hangshi Group
- Series C, Jun 29, 2020, $83M — China International Capital Corporation, CITIC Securities, Share Capital, Yingke Private Equity, Sangel Capital, Shenzhen Guozhong Venture Capital, Jiuyo Capital, Kaitou Hanrun Investment
- Series B, Oct 31, 2019, $43M — Share Capital, Yuexiu Industrial Investment Funds Management, Sangel Capital, Jiuyo Capital, ZCC Asset Management
- Series B, Nov 27, 2017 — Jiuyo Capital
- Series A, Jul 16, 2015 — Yuexiu Industrial Investment Funds Management, Qingdao Goldstone Haorui Investment, Zhejiang Xianju Pharmaceutical Co.,Ltd

## Investors

- Yuexiu Industrial Investment Funds Management (https://capitalatlas.ai/funds/yuexiu-industrial-investment-funds-management) — Series A, Series B
- Qingdao Goldstone Haorui Investment — Series A
- Zhejiang Xianju Pharmaceutical Co.,Ltd — Series A
- Jiuyo Capital (https://capitalatlas.ai/funds/jiuyo-capital) — Series B, Series C
- Share Capital (https://capitalatlas.ai/funds/share-capital) — Series B, Series C
- Sangel Capital (https://capitalatlas.ai/funds/sangel-capital) — Series B, Series C, Series D
- ZCC Asset Management (https://capitalatlas.ai/funds/zcc-asset-management) — Series B, Series D
- China International Capital Corporation (https://capitalatlas.ai/funds/china-international-capital-corporation) — Series C, Series D
- CITIC Securities — Series C
- Yingke Private Equity (https://capitalatlas.ai/funds/yingke-private-equity) — Series C, Series D
- Shenzhen Guozhong Venture Capital (https://capitalatlas.ai/funds/shenzhen-guozhong-venture-capital) — Series C
- Kaitou Hanrun Investment (https://capitalatlas.ai/funds/kaitou-hanrun-investment) — Series C
- TTGG Ventures (https://capitalatlas.ai/funds/ttgg-ventures) — Series D
- CR Capital (https://capitalatlas.ai/funds/cr-capital) — Series D
- HosenCare Brothers (https://capitalatlas.ai/funds/hosencare-brothers) — Series D
- Heda Venture (https://capitalatlas.ai/funds/heda-venture) — Series D
- Hangshi Group (https://capitalatlas.ai/funds/hangshi-group) — Series D